Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: A phase 2 placebo-controlled ANRS trial

AIDS

Volumn 24, Issue 14, 2010, Pages 2211-2223

  Salmon Céron, Dominique ^a   Durier, Christine ^b   Desaint, Corinne ^c   Cuzin, Lise ^d   Surenaud, Mathieu ^e   Hamouda, Nadine Ben ^e   Lelièvre, Jean Daniel ^f   Bonnet, Bénédicte ^g   Pialoux, Gilles ^h   Poizot Martin, Isabelle ^i,j   Aboulker, Jean Pierre ^b   Lévy, Yves ^f   Launay, Odile ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c Groupe Hospitalier Paris Centre   (France)

^d Hôpital Pur Pan   (France)

^e INSTITUT COCHIN   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HÔPITAL TENON   (France)

ⁱ HÔPITAL SAINTE MARGUERITE   (France)

^j ANRS   (France)

more..

Author keywords

cellular immune responses; HIV; lipopeptides; phase II clinical trial; vaccine

Indexed keywords

ALANYLISOLEUCYLPHENYLALANYLGLUTAMINYLSERYLSERYLMETHIONYLTHREONYLLYSYLISOLEUCYLLEUCYLGLUTAMYLPROLYLPHENYLALANYLARGINYLLYSYLGLUTAMINYLASPARAGINE; ALANYLISOLEUCYLPHENYLALANYLGLUTAMINYLSERYLSERYLMETHIONYLTHREONYLLYSYLISOLEUCYLLEUCYLGLUTAMYLPROLYLPHENYLALANYLARGINYLLYSYLGLUTAMINYLASPARAGINYLPROLYLASPARTYLISOLEUCYLVALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLMETHIONYLASPARTYLASPARTIC ACID; ASPARAGINYLPROLYLPROLYLISOLEUCYLPROLYLVALYLGLYCYLGLUTAMYLISOLEUCYLTYROSYLLYSYLARGINYLTRYPTOPHANYLISOLEUCYLISOLEUCYLLEUCYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUCYLVALYLARGINYLMETHIONYLTYROSYLSERYLPROLYLTHREONYLSERYLISOLEUCYLLEUCYLASPARTIC ACID; GLUTAMYLLYSYLISOLEUCYLARGINYLLEUCYLARGINYLPROLYLGLYCYLGLYCYLLYSYLLYSYLLYSYLTYROSYLLYSYLLEUCYLLYSYLHISTIDYLISOLEUCYLVALINE; HISTIDYLTHREONYLGLUTAMINYLGLYCYLTYROSYLPHENYLALANYLPROLYLASPARTYLTRYPTOPHANYLGLUTAMINYLASPARAGINYLTYROSYLTHREONYLPROLYLGLYCYLPROLYLGLYCYLVALYLARGINYLTYROSYLPROLYLLEUCYLTHREONYLPHENYLALANYLGLYCYLTRYPTOPHANYLCYSTEINYLTYROSYLLYSYLLEUCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEUCYLGLUTAMYLPROLYLPHENYLALANYLARGINYLLYSYLGLUTAMINYLASPARAGINYLPROLYLASPARTYLISOLEUCYLVALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLMETHIONYLASPARTYLASPARTYLLEUCYLTYROSINE; LIPO 5 VACCINE; LIPOPEPTIDE; PLACEBO; UNCLASSIFIED DRUG; VALYLGLYCYLPHENYLALANYLPROLYLVALYLTHREONYLPROLYLGLUTAMINYLVALYLPROLYLLEUCYLARGINYLPROLYLMETHIONYLTHREONYLTYROSYLLYSYLALANYLALANYLVALYLASPARTYLLEUCYLSERYLHISTIDYLPHENYLALANYLLEUCYLLYSYLGLUTAMYLLYSYLGLYCYLGLYCYLLEUCINE;

ADULT; AMINO ACID SEQUENCE; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FOLLOW UP; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; LIMB PAIN; LYMPHOCYTE PROLIFERATION; MIGRAINE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LIPOPEPTIDES; MALE; MIDDLE AGED;

EID: 77956231717     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ce566     Document Type: Article

References (26)

1. R T lymphocyte activation. Eur J Immunol 2000; 30:3256-3265.
2. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, et al. Two human immunodeficiency virus vaccinal lipopep-tides follow different cross-presentation pathways in human dendritic cells. J Virol 2003; 77:1564-1570.
3. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopep-tide vaccine. J Virol 2000; 74:1694-1703.
4. Pialoux G, Gahery-Segard H, Sermet S, Poncelet H, Fournier S, Gerard L, et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001; 15:1239-1249.
5. Salmon D, Gahery H, Silbermann B, Jackson A, Mazarin V, Souag N, et al. Safety and immunogenicity of HIV lipopeptides associated or not to a live HIV recombinant canarypox (ALVAC-HIV, vCP1452) in non-HIV-infected volunteers (ANRSVAC10) [abstract #57]. In: AIDS Vaccine; 30 August-1 September 2004; Lausanne, Switzerland; 2004.
6. Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, et al. Cellular immune responses induced with dose sparing intradermal administration of HIV vaccine to HIV uninfected volunteers in the ARNS VAC 16 Trial. PLoS One 2007; 2:e725.
7. Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-286.
8. R T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses 2006; 22:684-694.
9. Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, Girard PM, et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol 2008; 15:562-568.
10. R-T-cell epitopes recognized. J Virol 2003; 77:11220-11231.
11. Durier C, Launay O, Meiffrédy V, Sädi Y, Salmon D, Lévy Y, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006; 20: 1039-1049.
12. Klinguer C, David D, Kouach M, Wieruszeski JM, Tartar A, Marzin D, et al. Characterization of a multilipopeptide mixture used as an HIV-1 vaccine candidate. Vaccine 1999; 18:259-267.
13. Tassignon J, Burny W, Dahmani S, Zhou L, Stordeur P, Byl B, et al. Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-g production by ELISA, ELISPOT, flow cytometry and real-time PCR. J Immunol Methods 2005; 305:188-198.
14. R T-cell epi-topes. J Virol 2006; 80:4717-4728.
15. Frey S, Peiperl L, Baden L, McElrathJ, Wright P, Goepfert P, et al. Immunogenicity of ANRS LIPO-5 alone, Sanofi-Pasteur ALVAC-HIV(vCP1452) alone, and ALVAC HIV Prime/LIPO-5 boost in healthy, HIV-1 uninfected adult participants [abstract #P09B-21]. Antivir Ther 2006; 11 (Suppl 2):169-170.
16. Winstone N, Guimarães-Walker A, Roberts J, Brown D, Loach V, Goonetilleke N, et al. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 2009; 39:975-985.
17. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
18. Sun Y, Schmitz JE, Buzby AP, Barker BR, Rao SS, Xu L, et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006; 80:10950-10956.
19. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, et al. A CD4(R) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10:406-410.
20. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005; 175:5675-5680.
21. Flanagan K, Lee E, Gravenor M, Reece W, Urban B, Doherty T, et al. Unique T cell effector functions elicited by Plasmodium falciparum in Malaria-exposed Africans tested by three T cell assays. J Immunol 2001; 167:4729-4737.
22. Desombere I, Clement F, Rigole H, Leroux-Roels G. The duration of in vitro stimulation with recall antigens determines the subset distribution of interferon-g producing lymphoid cells: a kinetic analysis using the interferon-g secretion assay. J Immunol Meth 2005; 301:124-139.
23. R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
24. RollandM,HeckermanD,DengW,Rousseau CM, Coovadia H, Bishop K, et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008; 3:e1424.
25. Frey S, Peiperl L, Baden L, McElrath J, Wright P, Goepfert P, et al. Safety of ANRS LIPO-5 alone, sanofi-pasteur ALVAC-HIV(VCP1452) alone, and ALVAC HIV prime/LIPO-5 boost in healthy, HIV-1 uninfected adult participants [abstract #300P]. In: AIDS Vaccine; 6-9 September 2005; Montréal, Québec, Canada; 2005. p. 122.
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.